Despite the macrolide component, Pristinamycin is effective against erythromycin-resistant staphylococci and strepcococci. Importantly, Pristinamycin is active against methicillin-resistant Staphylococcus aureus (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an intravenous formulation owing to its poor solubility. Nevertheless it is sometimes used as an alternative to rifampicin + fusidic acid or linezolid for the treatment of MRSA.
The lack of an intravenous formulation led to the development of the pristinamycin-derivative quinupristin / dalfopristin (ie, Synercid), which may be administered intravenously for more severe MRSA infections.
Read more：http://www.acid-lactic-bacteria.com/bulk-drug/Pristinamycin/
No comments:
Post a Comment